Navigation Links
Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
Date:6/8/2012

e over all post-baseline visits
ataluren n=116; placebo n=116

2.5%

0.0478Patients not on chronic inhaled antibiotics
ataluren n=52; placebo n=53

6.7%

0.013**nominal p-valueReduction in pulmonary exacerbation rate over 48 weeks (ITT population)Ataluren vs. PlaceboDecrease in
exacerbation ratep-valueAll patients
ataluren n=116; placebo n=116

23%

0.0992Patients not on chronic inhaled antibiotics
ataluren n=52; placebo n=53

43%

0.014**nominal p-value

The tertiary endpoints of sweat test and nasal potential difference did not show an effect between ataluren and placebo. Preliminary data from an ongoing extension study support the sustained effect of ataluren on lung function as measured by FEV1. Further analyses of these data and other study endpoints will be reported at future scientific conferences when completed.

"This is a historic time for patients with cystic fibrosis," said Robert J. Beall, Ph.D., president and CEO, Cystic Fibrosis Foundation. "We are beginning to see the results of our commitment to the development of novel treatments for patients with cystic fibrosis. Promising therapeutic approaches that target the underlying cause of cystic fibrosis are fundamental to future therapeutic options that have the potential to change the course of the disease."

Safety results indicate that ataluren was generally well tolerated. The overall incidence of adverse events through Week 48 was similar in the ataluren and placebo groups. The most common adverse events were typical for CF and included pulmonary exacerbation, cough, and upper respiratory tract infection, which occurred at similar frequencies in the ataluren and placebo arms. Most of the serious adverse events, those requiring hospitalization, were pulmonary exacerbations unrelated to study treatment and some patients experienced creatinine elevations that occurred in connection with c
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
2. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
3. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
4. Sorrento Therapeutics Awarded Third Phase I STTR Grant
5. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
6. Interim Results Reported for Phase I Open-Label Clinical Trial for the Treatment of PTSD and MDD Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
7. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
8. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
9. Preliminary Phase 2 Data of Ocera Therapeutics OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction
10. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
11. Clinilabs Opens Phase I Unit In Eatontown, New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... -- Concord Medical Services Holdings Limited ("Concord Medical" or ... specialty hospital management solution provider and operator of the ... China , today announced that on ... special cash dividend of US$0.30 per ordinary share (or ... outstanding ordinary shares. The total expense for the special ...
(Date:7/28/2014)... July 28, 2014 ... 2,5 Millionen £ investiert hat, um die ... Gesundheits-, Pharma- und Logistikbranche zu erfüllen. Albion ...      (Photo: http://photos.prnewswire.com/prnh/20140728/697982 ) ... OmPrompt sein beschleunigtes Wachstum mit Investitionen in ...
(Date:7/28/2014)... MURRAY HILL and NEW PROVIDENCE, ... management and engineering professionals are invited to meet with ... Conference and Technical Exhibition to be held at McCormick ... August 3-6. "Hospitals demand nothing less ... said Mark Sanda , Linde,s Healthcare Segment manager. ...
Breaking Medicine Technology:Concord Medical Declares Special Dividend 2OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2
... , DENVER , Jan. 28 Global ... Board: GLOB), an international healthcare information technology company, today announced ... management software and Donor Doc® health history questionnaire to Community ... Kansas City, Missouri . Terms of the agreement were ...
... , , MOUNTAIN VIEW, Calif. ... announced the initiation of a Phase I clinical trial ... autoimmune diseases.  CCX168 is a highly potent and very ... a component of the body,s complement system and a ...
Cached Medicine Technology:Global Med Technologies(R)' Solution of Choice for Important Regional Blood Center 2Global Med Technologies(R)' Solution of Choice for Important Regional Blood Center 3Global Med Technologies(R)' Solution of Choice for Important Regional Blood Center 4Global Med Technologies(R)' Solution of Choice for Important Regional Blood Center 5ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 2ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 3ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 4
(Date:7/28/2014)... revised version of a surgical procedure to treat severe ... than 90 percent of the time in patients treated ... MGH Division of Plastic and Reconstructive Surgery report that ... non-endoscopic procedure all of whom had headaches associated ... relief a year later. The team,s paper has ...
(Date:7/28/2014)... Braintree, Massachusetts (PRWEB) July 28, 2014 ... the Summit Provider Exchange technology solution ... office integration efforts and support collaboration with their ... 242 bed acute-care medical center located in New ... 800,000 seasonal visitors with a variety of inpatient ...
(Date:7/28/2014)... runners are far more likely to die of heat ... new study. The researchers pointed out that ... actually 10 times more likely to develop severe and ... of a young and apparently healthy person due to ... gets a lot more media attention. "This research ...
(Date:7/28/2014)... July 28, 2014 The Oakwood Foundation ... Birkhill, Wang, Songe and Associates, PC that will benefit ... tomorrows to come. , The HBWS group is ... more than $2.5 million in donations. Through their latest ... for the Oakwood Women’s Healthcare Classic for the next ...
(Date:7/28/2014)... Stimulating one of two dopamine-producing regions in the brain ... either isoflurane or propofol. In the August issue ... (MGH) report that rats anesthetized with continuous doses of ... stand up in response to electrical stimulation delivered to ... other major dopamine-releasing area, the substantia nigra, did not ...
Breaking Medicine News(10 mins):Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2Health News:Stimulation of brain region restores consciousness to animals under general anesthesia 2
... CHESHIRE, Conn., Oct. 11 Alexion,Pharmaceuticals, Inc. (Nasdaq: ... conference call and audio web cast on Thursday, October ... with the release of its,financial results for the third ... results at 6:30 a.m. ET on Thursday,October 25, 2007. ...
... Oct. 11 The following was,written by Andrew ... hormonal birth control. Why can Planned,Parenthood freely market ... an increasing array of restrictions?, Fifty years ... were,lethal. Many people smoked, especially highly visible public ...
... The National Medical,Association (NMA) announced the appointment of ... Director of Health Policy, Mr. Sogie-Thomas,will be responsible ... emerging,healthcare trends and current policy issues. He will ... on state and federal law,regulation, and policy. ...
... Chinese undergraduates showed significant benefit , , , THURSDAY, Oct. ... a day for five days helped to increase energy ... of stress hormones, a small study found. , ... from traditional Chinese medicine, the study participants reported better ...
... World Bank report,says in just two years nearly 20 ... doses of artemisinin-based combination therapy (ACT),are on course to ... Control in Africa., The Progress Report on the ... --- including more than 42 million children under,age five ...
... Receives 2007 Distinctively Blue Award for Hospital ... efforts to,reduce hospital-acquired infections in the mid-Atlantic ... from the BlueCross BlueShield,Association of America. CareFirst ... Award for Innovations for the 100,000 Lives ...
Cached Medicine News:Health News:Sue Birth Control Companies for Your Health, Says American Life League 2Health News:Sue Birth Control Companies for Your Health, Says American Life League 3Health News:Sue Birth Control Companies for Your Health, Says American Life League 4Health News:National Medical Association Selects New Director of Health Policy 2Health News:Meditation a Quick Fix for Stress 2Health News:World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths 2Health News:World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths 3Health News:National Award Recognizes Delmarva Foundation and CareFirst BlueCross BlueShield Quality Improvement Efforts 2
PremierEdge Stab Knives - 15....
DCR Set, Straight....
... acknowledged to be the easiest to use, ... benefits are due to the exclusive use ... footprint available coupled with advanced electronics and ... reading. Thus corneal thickness measurements can be ...
... The Leica CM1850 cryostat for ... histopathology laboratory is designed for ... workload. A new insulation technology ... the refrigerating system and maintains ...
Medicine Products: